Bruker (NASDAQ:BRKR) Issues FY24 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.59-2.64 for the period, compared to the consensus earnings per share estimate of $2.63. The company issued revenue guidance of $3.38-3.44 billion, compared to the consensus revenue estimate of $3.40 billion. Bruker also updated its FY 2024 guidance to 2.590-2.640 EPS.

Bruker Price Performance

Bruker stock traded down $1.22 during trading hours on Wednesday, reaching $60.94. 1,086,000 shares of the stock were exchanged, compared to its average volume of 1,027,817. The stock has a 50 day moving average of $64.58 and a two-hundred day moving average of $75.85. The company has a market cap of $8.86 billion, a P/E ratio of 22.87, a price-to-earnings-growth ratio of 2.39 and a beta of 1.20. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95. Bruker has a twelve month low of $53.79 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The business had revenue of $800.70 million for the quarter, compared to analysts’ expectations of $799.44 million. During the same period last year, the firm posted $0.50 earnings per share. The firm’s quarterly revenue was up 17.4% compared to the same quarter last year. Equities analysts expect that Bruker will post 2.66 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 17th. Investors of record on Monday, June 3rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.33%. The ex-dividend date was Monday, June 3rd. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BRKR shares. The Goldman Sachs Group reduced their price target on shares of Bruker from $72.00 to $60.00 and set a sell rating on the stock in a research note on Tuesday, July 9th. Bank of America decreased their target price on shares of Bruker from $95.00 to $90.00 and set a buy rating on the stock in a research note on Monday, May 20th. StockNews.com downgraded Bruker from a buy rating to a hold rating in a report on Tuesday, May 21st. Stifel Nicolaus lowered their target price on Bruker from $81.00 to $77.00 and set a hold rating for the company in a report on Monday, May 20th. Finally, Jefferies Financial Group began coverage on Bruker in a research note on Monday, June 3rd. They set a buy rating and a $85.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $81.78.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.